In vitro three-dimensional modeling of fallopian tube secretory epithelial cells

BMC Cell Biology

Simon A Gayther⁴  Christopher Jones³  Ian J Jacobs²  Elizabeth Benjamin¹  Nathan Lee⁴  Maria Notaridou³  Kate Lawrenson⁴ 

[1] Department of Histopathology, Cancer Institute, University College London, Rockefeller Building, University Street, London WC1E 6JJ, UK;Faculty of Medical and Human Sciences, 1st Floor, Innovation Centre, Core Technology Facility, The University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK;Gynaecological Cancer Research Laboratories, UCL EGA Institute for Women’s Health, University College London, The Paul O’Gorman Building, Gower Street, London WC1E 6DD, UK;Department of Preventive Medicine, University of Southern California/Keck School of Medicine, 1450 Biggy Street, Los Angeles, California

关键词: Ovarian cancer;    Tissue microenvironment;    Three-dimensional in vitro models;    Gene expression microarray;    Fallopian tube secretory epithelial cells;   

Others  :  855123
DOI  :  10.1186/1471-2121-14-43

 received in 2013-03-25, accepted in 2013-09-23,  发布年份 2013

【 摘 要 】

Background

Fallopian tube secretory epithelial cells (FTSECs) have been implicated as a cell-of-origin for high-grade serous epithelial ovarian cancer. However, there are relatively few in vitro models of this tissue type available for use in studies of FTSEC biology and malignant transformation. In vitro three-dimensional (3D) cell culture models aim to recreate the architecture and geometry of tissues in vivo and restore the complex network of cell-cell/cell-matrix interactions that occur throughout the surface of the cell membrane.

Results

We have established and characterized 3D spheroid culture models of primary FTSECs. FTSEC spheroids contain central cores of hyaline matrix surrounded by mono- or multi-layer epithelial sheets. We found that 3D culturing alters the molecular characteristics of FTSECs compared to 2D cultures of the same cells. Gene expression profiling identified more than a thousand differentially expressed genes between 3D and 2D cultures of the same FTSEC lines. Pathways significantly under-represented in 3D FTSEC cultures were associated with cell cycle progression and DNA replication. This was also reflected in the reduced proliferative indices observed in 3D spheroids stained for the proliferation marker MIB1. Comparisons with gene expression profiles of fresh fallopian tube tissues revealed that 2D FTSEC cultures clustered with follicular phase tubal epithelium, whereas 3D FTSEC cultures clustered with luteal phase samples.

Conclusions

This 3D model of fallopian tube secretory epithelial cells will advance our ability to study the underlying biology and etiology of fallopian tube tissues and the pathogenesis of high-grade serous epithelial ovarian cancer.

【 授权许可】

   
2013 Lawrenson et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kurman RJ, Shih IM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 2011, 42(7):918-931.
• [2]Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB, McDonald JF: Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007, 104(2):331-337.
• [3]Henriksen T, Tanbo T, Abyholm T, Oppedal BR, Claussen OP, Hovig T: Epithelial cells from human fallopian tube in culture. Hum Reprod 1990, 5(1):25-31.
• [4]Fotheringham S, Levanon K, Drapkin R: Ex vivo culture of primary human fallopian tube epithelial cells. J Vis Exp 2011, (51):2728.
• [5]Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, et al.: Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010, 29(8):1103-1113.
• [6]Karst AM, Levanon K, Drapkin R: Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 2011, 108(18):7547-7552.
• [7]Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA: Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007, 12(2):160-170.
• [8]Jones PL, Schmidhauser C, Bissell MJ: Regulation of gene expression and cell function by extracellular matrix. Crit Rev Eukaryot Gene Expr 1993, 3(2):137-154.
• [9]Aggeler J, Ward J, Blackie LM, Barcellos-Hoff MH, Streuli CH, Bissell MJ: Cytodifferentiation of mouse mammary epithelial cells cultured on a reconstituted basement membrane reveals striking similarities to development in vivo. J Cell Sci 1991, 99(Pt 2):407-417.
• [10]Streuli CH, Schmidhauser C, Bailey N, Yurchenco P, Skubitz AP, Roskelley C, Bissell MJ: Laminin mediates tissue-specific gene expression in mammary epithelia. J Cell Biol 1995, 129(3):591-603.
• [11]Li ML, Aggeler J, Farson DA, Hatier C, Hassell J, Bissell MJ: Influence of a reconstituted basement membrane and its components on casein gene expression and secretion in mouse mammary epithelial cells. Proc Natl Acad Sci U S A 1987, 84(1):136-140.
• [12]Streuli CH, Bailey N, Bissell MJ: Control of mammary epithelial differentiation: basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity. J Cell Biol 1991, 115(5):1383-1395.
• [13]Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP: Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2009, 55(5):619.
• [14]Lawrenson K, Benjamin E, Turmaine M, Jacobs I, Gayther S, Dafou D: In vitro three-dimensional modelling of human ovarian surface epithelial cells. Cell Prolif 2009, 42(3):385-393.
• [15]Lawrenson K, Sproul D, Grun B, Notaridou M, Benjamin E, Jacobs IJ, Dafou D, Sims AH, Gayther SA: Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Carcinogenesis 2011, 32(10):1540-1549.
• [16]Lawrenson K, Grun B, Benjamin E, Jacobs IJ, Dafou D, Gayther SA: Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. Neoplasia 2010, 12(4):317-325.
• [17]Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA: Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008, 14(13):4067-4078.
• [18]George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, Virtanen C, Shaw PA: Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol 2011, 225(1):106-117.
• [19]Lee GY, Kenny PA, Lee EH, Bissell MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007, 4(4):359-365.
• [20]Yanai-Inbar I, Silverberg SG: Mucosal epithelial proliferation of the fallopian tube: prevalence, clinical associations, and optimal strategy for histopathologic assessment. Int J Gynecol Pathol 2000, 19(2):139-144.
• [21]McCauley TC, Buhi WC, Wu GM, Mao J, Caamano JN, Didion BA, Day BN: Oviduct-specific glycoprotein modulates sperm-zona binding and improves efficiency of porcine fertilization in vitro. Biol Reprod 2003, 69(3):828-834.
• [22]Kouba AJ, Abeydeera LR, Alvarez IM, Day BN, Buhi WC: Effects of the porcine oviduct-specific glycoprotein on fertilization, polyspermy, and embryonic development in vitro. Biol Reprod 2000, 63(1):242-250.
• [23]Donnez J, Casanas-Roux F, Caprasse J, Ferin J, Thomas K: Cyclic changes in ciliation, cell height, and mitotic activity in human tubal epithelium during reproductive life. Fertil Steril 1985, 43(4):554-559.
• [24]Bertuzzi A, Fasano A, Gandolfi A, Sinisgalli C: Necrotic core in EMT6/Ro tumour spheroids: is it caused by an ATP deficit? J Theor Biol 2010, 262(1):142-150.
• [25]Schaller G, Meyer-Hermann M: Continuum versus discrete model: a comparison for multicellular tumour spheroids. Philos Trans A Math Phys Eng Sci 2006, 364(1843):1443-1464.
• [26]Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al.: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5(12):e232.
• [27]Tong GX, Devaraj K, Hamele-Bena D, Yu WM, Turk A, Chen X, Wright JD, Greenebaum E: Pax8: a marker for carcinoma of Müllerian origin in serous effusions. Diagn Cytopathol 2011, 39(8):567-574.
• [28]Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS: PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010, 34(5):627-635.
• [29]Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, et al.: A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 2005, 365(9457):415-416.
• [30]Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, et al.: A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet 2005, 365(9457):412-415.
• [31]Network CGAR: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
• [32]Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al.: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2(5):401-404.
• [33]Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al.: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6(269):l1.
• [34]O’Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, Toy K, Rivers CS, Modrusan Z, Amler LC, et al.: Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008, 68(13):5380-5389.
• [35]Park EH, Kim S, Jo JY, Kim SJ, Hwang Y, Kim JM, Song SY, Lee DK, Koh SS: Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis 2013, 34(3):694-702.
• [36]Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, et al.: Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55. BioMed Central Full Text
• [37]Palter SF, Mulayim N, Senturk L, Arici A: Interleukin-8 in the human fallopian tube. J Clin Endocrinol Metab 2001, 86(6):2660-2667.
• [38]Laird SM, Hill CJ, Warren MA, Tuckerman EM, Li TC: The production of placental protein 14 by human uterine tubal epithelial cells in culture. Hum Reprod 1995, 10(6):1346-1351.
• [39]Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, et al.: A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009, 41(9):996-1000.
• [40]Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, et al.: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010, 42(10):880-884.
• [41]Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, et al.: A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010, 42(10):874-879.
• [42]Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE: Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013, 45(4):371-384. 384e371-372
• [43]Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X: Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 2013, 4:1627.
• [44]Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H: GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013, 45(4):362-370. 370e361-362
• [45]Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, et al.: Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013, 4:1628.
• [46]Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al.: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5(10):R80. BioMed Central Full Text
• [47]Kuhn K, Baker SC, Chudin E, Lieu MH, Oeser S, Bennett H, Rigault P, Barker D, McDaniel TK, Chee MS: A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res 2004, 14(11):2347-2356.
• [48]Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG: BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 2008, 24(24):2921-2922.
• [49]Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
• [50]Shi W, Oshlack A, Smyth GK: Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Res 2010, 38(22):e204.
• [51]Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98(9):5116-5121.
• [52]Alexa A, Rahnenführer J, Lengauer T: Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006, 22(13):1600-1607.
• [53]Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995, 1(51):298-300.